Elevated Liver Enzymes: Medical Definition, Root Causes, Symptoms and Long-Term Consequences

By Guillermo Salinas Araya · June 1, 2026 · Educational Material

In 1980, pathologist Jurgen Ludwig described in Mayo Clinic Proceedings an unnamed entity: fatty infiltration of the liver in patients who had never consumed alcohol. Forty-six years later, this finding affects one in three adults in the Western world.

Medical Definition of Elevated Liver Enzymes

The term elevated liver enzymes (transaminases) refers to a clinical condition with established diagnostic criteria in recent medical literature. Understanding it requires distinguishing between the entity itself, its presentation forms, and its underlying mechanisms. Updated international guidelines have reformulated several of these criteria over the past decade, expanding what conventional clinical practice has not yet fully incorporated.¹

Pathophysiology: How It Develops

The pathophysiological cascade of elevated liver enzymes involves multiple parallel mechanisms that feed back into each other. The monocausal hypothesis has been replaced by integrative models that recognize the interaction of several axes:²

• Endocrine-metabolic axis: altered insulin sensitivity and hepatic lipogenesis.
• Inflammatory axis: low-grade pro-inflammatory cytokines (TNF-α, IL-6, elevated high-sensitivity CRP).
• Mitochondrial axis: respiratory chain dysfunction and increased reactive oxygen species.
• Intestinal axis: microbiome alterations, increased intestinal permeability, endotoxin translocation.
• Neuroendocrine axis: dysregulation of the hypothalamic-pituitary-adrenal axis with chronically elevated cortisol.

The simultaneous accumulation of these five impacts is what distinguishes the pathological state from the physiological state of compensatory tolerance. A patient may spend years with one or two active axes without clinical manifestation — until convergence overwhelms adaptive mechanisms.

Clinical Signs and Symptoms

Clinical presentation is heterogeneous. In early stages, most patients are paucisymptomatic or asymptomatic.³ Signs and symptoms that guide diagnosis include:

• Unexplained fatigue, especially postprandial
• Progressive increase in abdominal circumference
• Skin changes (spots, skin tags, hair alterations)
• Sleep-wake cycle disturbances
• Neurocognitive symptoms: brain fog, difficulty concentrating, irritability
• Nonspecific laboratory findings: mildly elevated CRP, mild hepatic or lipid abnormalities often labeled as "high normal"
• Subtle ultrasound findings requiring targeted examination

Consequences if Left Unaddressed

The natural history of elevated liver enzymes without adequate intervention involves silent but predictable progression:⁴

• Increased cardiovascular risk independent of cholesterol
• Accelerated development of type 2 diabetes in patients with prediabetes
• Progression toward structural organ damage within 5 to 15 years
• Increased oncological risk documented in longitudinal cohorts
• Progressive functional deterioration that reduces quality of life and healthy life expectancy

The therapeutic window of opportunity — the period during which the condition is completely reversible — is proportional to exposure time and the number of pathophysiological axes involved. Each year lost without comprehensive intervention narrows that window.

Can It Be Reversed?

Contemporary clinical evidence is compelling: in pre-irreversible stages, reversal is possible. But it requires addressing all five pathophysiological axes simultaneously, not sequentially or in isolation. This is where conventional approaches fail: they intervene on a single axis and leave the other four active.

The educational protocol we designed — The Salinas Method — consists of 8 sequential phases. Each phase addresses a distinct mechanism in the cascade. Phases 1 and 2 prepare the cellular terrain and correct the microbiome. Phases 3 through 6 dismantle low-grade inflammation, mitochondrial dysfunction, insulin resistance, and cortisol axis disruption. Phases 7 and 8 consolidate the change and prevent relapse.

It's not a diet. It's not isolated fasting. It's not a supplement. It's a guided educational protocol, step by step, based on the most recent clinical evidence and designed so the patient understands the why behind each action.

References

1. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980. PubMed
2. Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease. J Hepatol. 2020. PubMed
3. Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease. Hepatology. 2016. PubMed
4. Tilg H, Moschen AR. Evolution of inflammation in NAFLD: multiple parallel hits hypothesis. Hepatology. 2010. PubMed
5. Chalasani N, et al. The diagnosis and management of NAFLD: practice guidance from AASLD. Hepatology. 2018. PubMed
6. Wong RJ, et al. NASH is the second leading etiology of liver disease. Gastroenterology. 2015. PubMed